1.郑州市第七人民医院(河南 郑州 450000)
2.成都中医药大学附属医院(四川 成都 610072)
康敏霞,女,主治医师,主要从事中西医结合治疗妇产科疾病临床研究工作
彭波,副教授;E-mail:22704141@qq.com
扫 描 看 全 文
康敏霞, 崔蕾蕾, 黄银娟, 等. 自拟益气解毒汤联合重组人干扰素α-2b对宫颈高危型HPV持续感染患者局部微生态环境及相关免疫功能指标的影响[J]. 上海中医药杂志, 2021,55(11):54-58.
Minxia KANG, Leilei CUI, Yinjuan HUANG, et al. Effect of self-made Yiqi Jiedu Decoction combined with recombinant human interferon α-2b on the local microecological environment and related immune function indexes in patients with cervical persistent high-risk HPV infection[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(11):54-58.
康敏霞, 崔蕾蕾, 黄银娟, 等. 自拟益气解毒汤联合重组人干扰素α-2b对宫颈高危型HPV持续感染患者局部微生态环境及相关免疫功能指标的影响[J]. 上海中医药杂志, 2021,55(11):54-58. DOI: 10.16305/j.1007-1334.2021.2007026.
Minxia KANG, Leilei CUI, Yinjuan HUANG, et al. Effect of self-made Yiqi Jiedu Decoction combined with recombinant human interferon α-2b on the local microecological environment and related immune function indexes in patients with cervical persistent high-risk HPV infection[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(11):54-58. DOI: 10.16305/j.1007-1334.2021.2007026.
目的,2,观察自拟益气解毒汤联合重组人干扰素α-2b对宫颈高危型人乳头瘤病毒(HPV)持续感染患者局部微生态环境及相关免疫功能指标的影响。,方法,2,纳入64例宫颈高危型HPV持续感染患者,按照随机数字表分为治疗组和对照组,每组各32 例。对照组患者给予重组人干扰素α-2b阴道泡腾片治疗,治疗组患者在对照组治疗基础上加用自拟益气解毒汤口服。两组疗程均为3个月。比较两组患者的HPV转阴情况;对所有患者的阴道微生态环境指标进行评估,包括阴道分泌物pH值、Nugent评分,比较两组患者的阴道微生态环境复常率;检测宫颈局部干扰素-γ(IFN-γ)以及白介素(IL)-4、IL-12水平。,结果,2,①治疗组患者HPV转阴总有效率为87.5%,对照组为62.5%,治疗组患者的HPV转阴情况优于对照组(,P,<,0.05)。②治疗组患者的阴道微生态环境复常率为84.4%,对照组为46.9%,治疗组患者的阴道微生态环境恢复情况优于对照组(,P,<,0.05);治疗后,两组患者的阴道分泌物pH值、Nugent评分较治疗前均明显降低(,P,<,0.05),且治疗组患者的阴道分泌物pH值、Nugent评分低于对照组(,P,<,0.05)。③治疗后,两组患者的宫颈局部IFN-γ、IL-12水平较治疗前均明显升高(,P,<,0.05),IL-4水平明显降低(,P,<,0.05),且治疗组患者的IFN-γ、IL-12水平高于对照组(,P,<,0.05),IL-4水平低于对照组(,P,<,0.05)。,结论,2,自拟益气解毒汤联合重组人干扰素α-2b治疗宫颈高危型HPV持续感染,能够有效改善宫颈局部微生态环境,提高HPV转阴率和局部免疫功能。
Objective,2,To observe the effect of self-made Yiqi Jiedu Decoction combined with recombinant human interferon α-2b on the local microecological environment and related immune function indexes in patients with cervical persistent high-risk human papilloma virus (HPV) infection., Methods,2,A total of 64 patients with cervical persistent high-risk HPV infection were included and divided into the treatment group and control group according to the random number table, 32 cases in each group. The patients in the control group were treated with recombinant human interferon α-2b vaginal effervescent tablet, and the patients in the treatment group were orally treated with self-made Yiqi Jiedu Decoction based on the treatment of the control group. The treatment course of both groups was three months. The HPV negative change was compared between the two groups; the indexes of vaginal microecological environment were evaluated including the pH value of vaginal secretions and Nugent score, and the recovery rate of vaginal microecological environment was compared; the interferon-γ (IFN-γ), interleukin (IL)-4 and IL-12 levels of cervix were detected.,Results,2,①The total effective rate of HPV negative change was 87.5% in the treatment group and was 62.5% in the control group, and the HPV negative change in the treatment group was better than that in the control group (,P,<,0.05). ②The recovery rate of vaginal microecological environment was 84.4% in the treatment group and was 46.9% in the control group, and the recovery of vaginal microecological environment in the treatment group was better than that in the control group (,P,<,0.05); after treatment, the pH value of vaginal secretions and Nugent score in the two groups were significantly decreased compared with those before treatment (,P,<,0.05), and the pH value of vaginal secretions and Nugent score in the treatment group were lower than those in the control group (,P,<,0.05). ③After treatment, the IFN-γ and IL-12 levels of cervix in the two groups were significantly increased compared with those before treatment, the level of IL-4 was significantly decreased (,P,<,0.05), and the levels of IFN-γ and IL-12 in the treatment group were higher than those in the control group (,P,<,0.05) and the level of IL-4 was lower than that in the control group (,P,<,0.05).,Conclusion,2,Self-made Yiqi Jiedu Decoction combined with recombinant human interferon α-2b can effectively improve the local microecological environment of cervix and enhance the HPV negative rate and local immune function in the treatment of cervical persistent high-risk HPV infection.
高危型人乳头瘤病毒感染宫颈癌自拟益气解毒汤重组人干扰素α-2b局部微生态环境免疫指标
high-risk HPV infectioncervical cancerself-made Yiqi Jiedu Decoctionrecombinant human interferon α-2blocal microecological environmentimmune index
徐新亚, 张科群. 健脾化湿解毒方联合西药治疗慢性宫颈炎合并高危型HPV感染的临床研究[J]. 上海中医药杂志,2018, 52(10): 54-56,59.
BARROS M R, DE MELO C M L, BARROS M L C M G R, et al. Activities of stromal and immune cells in HPV-related cancers[J]. J Exp Clin Cancer Res, 2018(37): 137.
张雪芳,何鑫,黄文阳,等. 中国女性宫颈高危型HPV感染与阴道微生态关系的Meta分析[J]. 首都医科大学学报,2018, 39(6): 841-848.
崔艳双,余世强,王婵丽,等. 宫颈高危型HPV感染对阴道微生态及宫颈细胞免疫的影响[J]. 中国生育健康杂志,2018, 29(5): 453-456.
何晶,张烽,朱佳尔. 抗HPV生物蛋白敷料与重组人干扰素α-2b凝胶治疗高危型HPV感染的研究[J]. 中华医院感染学杂志,2020, 30(3): 403-408.
曹泽毅. 中华妇产科学[M]. 3版. 北京:人民卫生出版社,2014:2102-2109.
张玉珍. 中医妇科学[M]. 2版. 北京:中国中医药出版社,2007:183-190.
中华医学会妇产科学分会感染性疾病协作组. 阴道微生态评价的临床应用专家共识[J]. 中华妇产科杂志,2016, 51(10): 721-723.
谢建萍,杨志红,伊芳,等. 宫颈高危型人乳头瘤病毒感染与阴道菌群及宫颈局部免疫功能的关系[J]. 中华医院感染学杂志,2017, 27(10): 2336-2339.
周丽丽,薛金铃. 干扰素联合保妇康栓治疗宫颈高危型HPV 感染疗效及对阴道微生态环境的影响分析[J]. 世界复合医学,2019, 5(2): 20-22.
麦碧,胡桂英,刘婷艳,等. 干扰素联合保妇康栓治疗宫颈高危型HPV感染疗效及对阴道微生态环境的影响[J]. 中国实用医药,2018, 13(36): 141-143.
魏绍斌,邓琳雯,王妍. 杨家林名老中医学术思想与临证思辨特点[J]. 时珍国医国药,2015, 26(6): 1504-1505.
班胜. 班秀文教授治疗带下病经验总结[J]. 云南中医中药杂志,2018, 39(3): 1-3.
李波. 白花蛇舌草的化学成分和药理作用研究进展[J]. 天津药学,2016, 28(5): 75-78.
刘丽芳,李方洲. 板蓝根化学成分、药理及质量控制管理[J]. 中国卫生产业,2018, 15(13): 36-37.
樊琪,商亚珍. 半枝莲提取成分及其药理学研究进展[J]. 中医学,2018, 7(5): 271-275.
毕天琛,杨国宁,马海春. 中药薏苡仁化学成分及药理活性研究进展[J]. 海峡药学,2019, 31(11): 52-56.
陈倩雯,李娜,郭姝,等. 瞿麦的网络药理学研究[J]. 中药新药与临床药理,2019, 30(7): 829-836.
肖扬,李国政. 萆薢药理作用研究进展[J]. 山西中医,2018, 34(7): 54-56.
李娃,杨春娟,成聪聪,等. 基于网络药理学技术的中药地榆活性成分及药理作用研究[J]. 世界科学技术-中医药现代化,2019, 21(7): 1336-1345.
舒迎霜,贺漾初,曹护群,等. 黄芪多糖对犬血清免疫球蛋白、IFN-γ水平及分泌型IgA表达的影响[J]. 西北农业学报,2019, 28(2): 176-182.
洪慧,王鹤,贾超颖,等. HR-HPV感染后宫颈微环境中免疫炎症因子变化[J]. 安徽医学,2014, 35(1): 9-12.
张艳,李宁丽. 人类乳头瘤病毒免疫致病机制[J]. 现代免疫学,2006, 26(6): 523-526.
0
浏览量
292
下载量
0
CSCD
12
CNKI被引量
关联资源
相关文章
相关作者
相关机构